Skip to main content

Table 1 Patient characteristics with HR + , HER2-, pT1-3 invasive ductal and lobular cancer

From: Histologic tumor type as a determinant of survival in hormone receptor-positive, HER2-negative, pT1-3 invasive ductal and lobular breast cancer

 

IDC

ILC

p-value*

 

n (%)

n (%)

 

Patients

1586 (86.1 of total)

257 (13.9 of total)

 

Age (years)

0.26

 ≤ 39

88 (5.5)

7 (2.7)

 

40–49

334 (21.1)

57 (22.2)

 

50–59

476 (30.0)

70 (27.2)

 

60–69

403 (25.4)

70 (27.2)

 

 ≥ 70

285 (18.0)

53 (20.6)

 

pT

 < 0.001

1

1109 (69.9)

106 (41.2)

 

2

439 (27.7)

118 (45.9)

 

3

38 (2.4)

33 (12.8)

 

pN

0.02

0

988 (64.2)

144 (57.4)

 

1

418 (27.2)

71 (28.3)

 

2

99 (6.4)

25 (10.0)

 

3

34 (2.2)

11 (4.4)

 

Missing

47

6

 

LVSI

0.009

No

878 (65.4)

155 (74.5)

 

Yes

465 (34.6)

53 (25.5)

 

Missing

243

49

 

Grading

 < 0.001

1

220 (14.2)

8 (3.8)

 

2

828 (53.6)

156 (73.9)

 

3

498 (32.2)

47 (22.3)

 

Missing

40

46

 

ER Allred score

0.028

 ≤ 6

104 (10.3)

12 (5.5)

 

7–8

906 (89.7)

206 (94.5)

 

Missing

576

29

 

Ki-67 (%)

 < 0.001

 ≤ 9

124 (27.7)

42 (37.8)

 

10–19

146 (32.7)

49 (44.1)

 

 ≥ 20

177 (39.6)

20 (18.0)

 

Missing

1139

146

 
  1. Percentages are calculated within each group, i.e. IDC or ILC, except for the number of “Patients” indicated as % of total
  2. IDC invasive ductal cancer, ILC invasive lobular cancer, pT pathological tumor size, pN pathological lymph node status, LVSI lymphovascular space invasion, ER estrogen receptor
  3. *p-value for χ2 test